Canada Immunoglobulins Market Size, Share & Industry Analysis, By Product Type (Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIg)), By Indication (Primary Immunodeficiency (PI), Secondary Immunodeficiency (SID), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Immune Thrombocytopenic Purpura (ITP), Guillain Barré Syndrome and Others), By End User (Hospitals & ASCs, Specialty Clinics and Others), and Forecasts, 2025-2032

The Canada immunoglobulins market size was valued at USD 771.5 million in 2024. The market is projected to grow from USD 783.2 million in 2025 to USD 1,025.4 million by 2032, exhibiting a CAGR of 3.92% during the forecast period.

The Canadian marketspace for immunoglobulins is witnessing a steady growth primarily driven by rising diagnoses of primary and secondary immunodeficiency. Immunoglobulins are the most widely used plasma derived medicines in Canada and are considered essential, life-saving therapies within the healthcare system. Due to heavy reliance on imported plasma, the country is now focusing on expansion of plasma collection and increase in self-sufficiency.

Furthermore, many key industry players, including Grifols S.A and others are investing in strategic initiatives to maintain their competitive edge.

MARKET DYNAMICS

MARKET DRIVERS:

Rising Prevalence and Better Diagnosis of PI & SID to Drive Market Growth

The rising prevalence and better diagnosis of PI & SID is anticipated to boost the Canada immunoglobulins market growth significantly. With the increasing adoption of advanced diagnostic procedures for earlier and more accurate diagnosis of PI, the demand for immunoglobulins is constantly increasing. This is also supported by increasing awareness among population in Canada. Moreover, supportive guidelines from regulatory authorities also boost the consumption of immunoglobulins for PI and SID.

• For instance, the Ontario IG Utilization Management explicitly recommend Ig replacement to prevent recurrent severe infections in eligible SID patients.

MARKET RESTRAINTS:

Variability in Clinical Guidelines and Utilization Practices to Restrict Market Growth

A significant variability in clinical guidelines and utilization practices across provinces remain a major restraint limiting the market growth. Canada currently lacks a uniform, Pan-Canadian set of Ig guidelines; instead, each province has its own criteria for indications, dosing, and continuation of immunoglobulin therapy. This results in inconsistency across utilization practices in turn hampering the overall market growth.

• For instance, according to a study published in National Center for Biotechnology Information (NCBI) in September 2023, there are considerable variations among the existing provincial guidelines, which cause differences in IG utilization across Canada.

MARKET OPPORTUNITIES:

Push Toward Domestic Self-Sufficiency and Expansion of Domestic Plasma Collection Offers Lucrative Growth Opportunities

The significant shift toward domestic immunoglobulin supply chain in Canada presents a major market opportunity for plasma-derived product manufacturers and service providers. In recent years, the operating players and regulatory bodies are actively focusing on increasing self-sufficiency and expansion of domestic plasma collection to capture the untapped avenues of the market.

• For instance, the long term collaboration between Canadian Blood Services (CBS) and Grifols is aimed at boosting Canada’s self-sufficiency and establishment of the country’s first end-to-end domestic Ig supply chain.

CANADA IMMUNOGLOBULINS MARKET TRENDS:

Rapid Growth of Subcutaneous Immunoglobulin (SCIg) and Home-Based Therapy is a Emerging Market Trend

A key emerging trend in the market is the shift from hospital-based IVIG infusions toward home-based subcutaneous immunoglobulin (SCIg) therapy. This trend is especially observed for chronic indications such as primary and secondary immunodeficiency. This transition is driven by patient convenience, healthcare system efficiency, and strong economic evidence.

• For instance, according to a study published in Springer Nature Link in November 2022, self-administered SCIg is comparatively less costly from a health care payer perspective in Canada.

MARKET CHALLENGES:

Supply Vulnerability & Dependence on Plasma Industry Pose a Significant Challenge for Market

Supply vulnerability & dependence on plasma industry is a major challenge limiting the market growth. The heavy reliance on imported plasma products and finished Ig products makes the Canadian market vulnerable to fluctuations in global market. As demand for immunoglobulin therapies continues to rise across the world, any disruption in international plasma collection, manufacturing, or export policies directly results in product shortages, brand switches, or tightened clinical criteria in Canada, thereby constraining market growth.

• For instance, according to a study published in National Center for Biotechnology Information (NCBI) in September 2023, concerns have been raised due to the country’s high dependence on suppliers from other nations, mainly the U.S. to meet growing Ig demands.

Download Free sample to learn more about this report.

Segmentation Analysis

By Product Type

Rising Usage of Intravenous IG to Propel Segmental Growth

Based on the product type, the market is divided into intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg).

To know how our report can help streamline your business, Speak to Analyst

The intravenous immunoglobulin (IVIg) segment is expected to dominate the market during the forecast period with largest market share. The dominance of the segment is attributed to their widespread usage for broad range of indications, supportive reimbursement framework and high demand from healthcare professionals.

• For instance, Gammagard Liquid, Gamunex, and Privigen are some of the leading products approved in Canada.

Moreover, the subcutaneous immunoglobulin (SCIg) segment is expected to grow at a CAGR of 10.48% during the forecast period.

By Indication

High Usage of Immunoglobulins for Primary Immunodeficiency to Drive Segmental Growth

Based on the Indication, the market is segmented into primary immunodeficiency (PI), secondary immunodeficiency (SID), chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenic purpura (ITP), Guillain Barré syndrome, and others.

In 2024, the primary immunodeficiency segment held the largest Canada immunoglobulins market share based on indication. The segment's dominance can be attributed to chronic, lifelong need for immunoglobulin replacement in patients coupled with increasing recommendation of Ig as the standard-of-care therapy. Additionally, this growing demand is also driven by large PI patient pool in Canada. Furthermore, the segment is set to hold 37.9% share in 2025.

• For instance, according to the data published by Immunodeficiency Canada, primary immunodeficiency affects approximately 29,000 Canadians.

Additionally, the chronic inflammatory demyelinating polyneuropathy segment is projected to grow at a CAGR of 5.44% during the study period.

By End User

High Patient Volume to Lead the Segmental Growth of Hospitals & ASCs

Based on end user, the market is segmented into hospitals & ASCs, specialty clinics, and others.

In 2024, the market was primarily driven by hospitals & ASCs with the leading market share. Furthermore, the hospitals & ASCs segment is set to hold a 65.4% share in 2025. The dominance of this segment is supported by key factors such as high patient volume in these settings, and availability of clinical infrastructure and monitoring for safe and effective Ig administration.

• For instance, according to a survey published by Ontario Regional Blood Coordinating Network in November 2021, hospital-based transfusion service laboratories are the central point for receiving and reviewing Ig orders, reflecting heavy reliance on hospital infrastructure for Ig administration.

In addition, the specialty clinics segment is projected to grow at a CAGR of 5.58% during the study period.

COMPETITIVE LANDSCAPE

Key Industry Players:

Strategic Collaborations by Key Players to Strengthen their Market Positions

The market reflects a highly consolidated structure, with prominent players such as Grifols, S.A., CSL Behring LLC., and Takeda Pharmaceutical Company Limited holding the majority of the market share in 2025. The dominance of these companies is attributed to factors such as strong manufacturing capabilities, widespread plasma-collection networks, and long-term supply partnerships with national procurement bodies such as Canadian Blood Services (CBS) and Héma-Québec.

• For instance, in September 2022, Grifols signed a long-term collaboration agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada.

LIST OF KEY CANADA IMMUNOGLOBULINS MARKET PROFILED:

• Grifols, S.A. (Spain)
• CSL Behring LLC. (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Octapharma AG (Switzerland)

KEY INDUSTRY DEVELOPMENTS:

• March 2025: Takeda Canada Inc. received expanded market authorization for HyQvia from Health Canada for chronic inflammatory demyelinating polyneuropathy (CIDP).
• June 2023: Grifols S.A. signed an agreement with Canadian Plasma Resources (CPR) through which the company secured rights to obtain plasma donated in CPR centers.
• April 2023: Takeda Canada Inc. signed a three-year agreement with Canadian Blood Services (CBS) for immunoglobulin products.
• July 2022: Takeda Canada Inc. received expanded market authorization for HyQvia from Health Canada for primary humoral immunodeficiency (PI) and secondary humoral immunodeficiency (SI) in adult patients.
• February 2021: CSL Behring introduced a new patient support programs named Hizentra CARE Program in Canada.

REPORT COVERAGE

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation